Susquehanna Fundamental Investments LLC Buys Shares of 91,886 BioMarin Pharmaceutical Inc. $BMRN

Susquehanna Fundamental Investments LLC acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 91,886 shares of the biotechnology company’s stock, valued at approximately $5,258,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of BioMarin Pharmaceutical in the second quarter worth about $39,000. CIBC Private Wealth Group LLC boosted its holdings in shares of BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 179 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of BioMarin Pharmaceutical during the third quarter worth $40,000. Parallel Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 295 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new position in BioMarin Pharmaceutical in the 2nd quarter worth $56,000. Institutional investors own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BMRN. Royal Bank Of Canada cut their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Wall Street Zen raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Jefferies Financial Group lifted their price objective on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings cut shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Finally, The Goldman Sachs Group began coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They issued a “neutral” rating and a $69.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $88.92.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: The agreement removes a significant legal and competitive overhang for BioMarin and provides for royalty payments on Yuviwel sales in the U.S., European Union, Brazil and South Korea. Investors viewed the resolution as a potentially valuable new revenue stream while reducing litigation uncertainty. BioMarin Announces Global Settlement With Ascendis Pharma
• Positive Sentiment: Jefferies raised its price target on BMRN from $104 to $105 and reiterated a “buy” rating, implying substantial potential upside based on the firm’s valuation. Jefferies Raises BioMarin Price Target
• Neutral Sentiment: Market coverage characterized the patent settlement as a clean removal of an overhang, but analysts broadly kept their existing ratings unchanged, suggesting the news improves visibility without yet prompting a major reassessment of BioMarin’s outlook. Street Commentary on BioMarin and Ascendis
• Negative Sentiment: HC Wainwright raised its target only modestly, from $59 to $60, while maintaining a “neutral” rating. The target remains below the prevailing share price, highlighting valuation concerns and the possibility that some settlement benefits are already reflected in BMRN. HC Wainwright Raises BioMarin Price Target

BioMarin Pharmaceutical Stock Up 0.9%

NASDAQ:BMRN opened at $65.23 on Tuesday. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The firm has a market capitalization of $12.63 billion, a price-to-earnings ratio of 176.30, a price-to-earnings-growth ratio of 0.46 and a beta of 0.24. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The stock’s 50 day moving average price is $61.88 and its two-hundred day moving average price is $58.19.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The firm’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts expect that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.